IL102372A - Pharmaceutical composition containing quisqualate or kainate receptor antagonist - Google Patents

Pharmaceutical composition containing quisqualate or kainate receptor antagonist

Info

Publication number
IL102372A
IL102372A IL102372A IL10237292A IL102372A IL 102372 A IL102372 A IL 102372A IL 102372 A IL102372 A IL 102372A IL 10237292 A IL10237292 A IL 10237292A IL 102372 A IL102372 A IL 102372A
Authority
IL
Israel
Prior art keywords
withdrawal
quisqualate
treatment
nmda
withdrawal symptoms
Prior art date
Application number
IL102372A
Other languages
English (en)
Other versions
IL102372A0 (en
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL102372A0 publication Critical patent/IL102372A0/xx
Publication of IL102372A publication Critical patent/IL102372A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL102372A 1991-07-09 1992-06-30 Pharmaceutical composition containing quisqualate or kainate receptor antagonist IL102372A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4123106A DE4123106A1 (de) 1991-07-09 1991-07-09 Arzneimittel zur behandlung von entzugssymptomen

Publications (2)

Publication Number Publication Date
IL102372A0 IL102372A0 (en) 1993-01-14
IL102372A true IL102372A (en) 1998-06-15

Family

ID=6435996

Family Applications (1)

Application Number Title Priority Date Filing Date
IL102372A IL102372A (en) 1991-07-09 1992-06-30 Pharmaceutical composition containing quisqualate or kainate receptor antagonist

Country Status (10)

Country Link
US (1) US5385903A (fr)
EP (1) EP0527540A1 (fr)
JP (1) JPH0648959A (fr)
AU (1) AU660471B2 (fr)
CA (1) CA2073396A1 (fr)
DE (1) DE4123106A1 (fr)
HU (1) HUT61466A (fr)
IE (1) IE922232A1 (fr)
IL (1) IL102372A (fr)
ZA (1) ZA925146B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
DE4222826A1 (de) * 1992-07-09 1994-01-13 Schering Ag Arzneimittel zur Verhinderung der Toleranzentwicklung während der Behandlung mit Benzodiazepin-Rezeptor-Bindenen Wirkstoffen
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CA2440284A1 (fr) * 2001-03-08 2002-09-19 Emory University Antagonistes du recepteur nmda dependant du ph
EP2422773A3 (fr) * 2002-09-20 2012-04-18 Alpharma, Inc. Séquestration de sous-unité et compositions et procédés associés
PT2719378T (pt) * 2006-06-19 2016-11-02 Alpharma Pharmaceuticals Llc Composições farmacêuticas
KR20100045983A (ko) * 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
WO2009088673A2 (fr) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Composition pharmaceutique
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US11045462B2 (en) 2016-06-14 2021-06-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods for treating neurological conditions and exposure to nerve agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975430A (en) * 1989-06-16 1990-12-04 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University CNQX and its analogs as therapeutics for degenerative neural diseases
US5095009A (en) * 1990-04-11 1992-03-10 Merrell Dow Pharmaceuticals Inc. NMDA antagonists

Also Published As

Publication number Publication date
EP0527540A1 (fr) 1993-02-17
AU660471B2 (en) 1995-06-29
IE922232A1 (en) 1993-01-13
ZA925146B (en) 1993-08-16
HUT61466A (en) 1993-01-28
CA2073396A1 (fr) 1993-01-10
DE4123106A1 (de) 1993-01-14
JPH0648959A (ja) 1994-02-22
AU1956092A (en) 1993-01-14
HU9202261D0 (en) 1992-10-28
US5385903A (en) 1995-01-31
IL102372A0 (en) 1993-01-14

Similar Documents

Publication Publication Date Title
Baldessarini et al. Pharmacotherapy of psychosis and mania
EP1066038B1 (fr) Utilisation de cabergoline pour traiter les impatiences des membres inferieurs
JP6235962B2 (ja) オキシコドンおよびナロキソンを含有する剤形
RU2336871C2 (ru) Применение соединений, которые являются эффективными как селективные модуляторы опиатного рецептора
US3947579A (en) Method and composition for potentiating neuroleptic drugs
JP2016020385A (ja) 治療処置の副作用の低減のための方法および組成物
HU212271B (en) Process to prepare pharmaceutical compositions contg. baclofen for treating cough
US20200323823A1 (en) Methods for the treatment of depression
IL102372A (en) Pharmaceutical composition containing quisqualate or kainate receptor antagonist
JP2008189676A (ja) 末梢または中枢神経障害およびサイトカイン過剰産生の治療のためのｋ−２５２ａ誘導体の使用
Brackett et al. Prevention of cocaine-induced convulsions and lethality in mice: effectiveness of targeting different sites on the NMDA receptor complex
AU579028B2 (en) Anticonvulsant compositions and method
US20040266737A1 (en) Compounds of use in the treatment of epilepsy, seizure, and electroconvulsive disorders
US5998473A (en) Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester derivatives
US20220125803A1 (en) Methods for the treatment of perimenopause and menopause
US20240197756A1 (en) Methods of treatment with neuroactive steroids
US6326400B1 (en) N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its derivatives for appetite enhancement
WO2023028519A2 (fr) Méthodes de traitement de troubles liés à l'usage de substance
Pfaus The role of brain dopamine systems in anticipatory and consummatory aspects of sexual behavior in the male rat
US20080269276A1 (en) Compositions useful for treating irritable bowel syndrome
JPH08231399A (ja) モルヒネ禁断抑制作用剤
WO2013158837A1 (fr) Méthodes et compositions de traitement du trouble d'hyperactivité avec déficit de l'attention
EP1477168A1 (fr) Utilisation de la cabergoline pour traiter le syndrome de l'acroparesthésie nocturne

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees